BSE Live
Apr 21, 16:01Prev. Close
210.80
Open Price
210.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 21, 15:55Prev. Close
210.18
Open Price
210.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
210.50 (3506)
| Profit & Loss account of Suven Life Sciences (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 6.66 | 11.69 | 13.54 | 11.84 | 13.48 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 6.66 | 11.69 | 13.54 | 11.84 | 13.48 | |
| Total Operating Revenues | 6.66 | 11.69 | 13.54 | 11.84 | 13.48 | |
| Other Income | 10.73 | 21.13 | 8.45 | 5.32 | 7.75 | |
| Total Revenue | 17.38 | 32.82 | 21.99 | 17.16 | 21.23 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Employee Benefit Expenses | 20.82 | 16.53 | 15.77 | 17.46 | 15.29 | |
| Finance Costs | 0.05 | 0.16 | 0.29 | 0.53 | 0.82 | |
| Depreciation And Amortisation Expenses | 5.82 | 6.50 | 6.54 | 4.39 | 4.35 | |
| Other Expenses | 37.77 | 26.10 | 25.51 | 31.02 | 28.74 | |
| Total Expenses | 64.46 | 49.29 | 48.12 | 53.41 | 49.19 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | -47.08 | -16.47 | -26.13 | -36.25 | -27.95 | |
| Exceptional Items | 0.00 | 7.46 | 6.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | -47.08 | -9.01 | -20.13 | -36.25 | -27.95 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 0.00 | 0.00 | 0.00 | 0.00 | -5.70 | |
| Tax For Earlier Years | 0.00 | -1.00 | 0.00 | 0.00 | 0.38 | |
| Total Tax Expenses | 0.00 | -1.00 | 0.00 | 0.00 | -5.32 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | -47.08 | -8.01 | -20.13 | -36.25 | -22.63 | |
| Profit/Loss From Continuing Operations | -47.08 | -8.01 | -20.13 | -36.25 | -22.63 | |
| Profit/Loss For The Period | -47.08 | -8.01 | -20.13 | -36.25 | -22.63 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | -2.16 | -0.37 | -1.13 | -2.84 | -1.78 | |
| Diluted EPS (Rs.) | -2.16 | -0.37 | -1.13 | -2.84 | -1.78 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
30.01.2026
Suven Life Sci Consolidated December 2025 Net Sales at Rs 2.81 crore, up 74.46% Y-o-Y
30.01.2026
Suven Life Sci Standalone December 2025 Net Sales at Rs 2.81 crore, up 74.46% Y-o-Y
17.11.2025
Suven Life Sci Consolidated September 2025 Net Sales at Rs 0.92 crore, down 64.27% Y-o-Y
12.11.2025
Suven Life Sci Standalone September 2025 Net Sales at Rs 0.92 crore, down 64.27% Y-o-Y
30.01.2026
Suven Life Sci Consolidated December 2025 Net Sales at Rs 2.81 crore, up 74.46% Y-o-Y
30.01.2026
Suven Life Sci Standalone December 2025 Net Sales at Rs 2.81 crore, up 74.46% Y-o-Y
17.11.2025
Suven Life Sci Consolidated September 2025 Net Sales at Rs 0.92 crore, down 64.27% Y-o-Y
12.11.2025
Suven Life Sci Standalone September 2025 Net Sales at Rs 0.92 crore, down 64.27% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth